Stem Cell Therapy for Adenomyosis: MSC Therapy for Heavy Bleeding & Chronic Pelvic Pain

Adenomyosis affects an estimated 20–35% of women who develop pelvic symptoms — up to 70% of hysterectomy specimens — and is one of the most common, most undertreated causes of heavy periods and chronic pelvic pain [1].

Why surgery is often the default — and why it's final. For years the standard options were hormonal suppression, painkillers, or hysterectomy. Hysterectomy ends the bleeding, but it ends fertility, and for a condition that peaks in women in their 40s and 50s — often before they're done having children or before they're ready for major surgery — it's a heavy price. Uterine-sparing options exist (uterine artery embolization, MRI-guided focused ultrasound, endometrial ablation), but their durability for adenomyosis specifically is limited, partly because the disease is diffuse: the abnormal endometrial glands and stroma are woven through the myometrium, not confined to a single lesion [2].

The tissue-level problem is inflammation and scarring. Adenomyosis is not just "endometrium in the wrong place." The ectopic glands sit inside a microenvironment of chronic inflammation: macrophage infiltration, stromal fibrosis, angiogenesis, and — crucially — impaired apoptosis of the ectopic endometrial cells, which keeps them alive and proliferating instead of clearing them the way a normal menstrual shedding would [3]. That microenvironment is exactly the kind of inflammatory-fibrotic niche that mesenchymal stem cells (MSCs) have been studied to modulate across a wide range of conditions.

MSC therapy targets the biology, not the symptom. Rather than shrinking lesions or suppressing hormones, MSC-derived paracrine signaling aims to calm the immune cascade, restore normal tissue turnover, and limit the fibrotic response that thickens the uterine wall and distorts the cavity. It is early-stage, and no guideline endorses it yet — but the mechanistic and preclinical case is real, and a small body of clinical data is emerging.

What Is Adenomyosis?

Adenomyosis is a condition in which endometrial glands and stroma — the tissue that normally lines the inside of the uterus — grow invasively into the myometrium, the muscular wall of the uterus, where they continue to respond to hormonal cycling [4]. The result is a thickened, often asymmetric, myometrium with a characteristic disruption of the junctional zone on MRI, and a uterine cavity that can become distorted and enlarged.

Two clinical forms are recognized. The more common is diffuse adenomyosis, in which ectopic endometrial foci are scattered throughout the myometrium — particularly in the posterior wall and fundus. The rarer adenomyoma (or focal adenomyosis) presents as a discrete, often well-circumscribed nodule within the myometrium and can be difficult to distinguish from a fibroid on imaging or at surgery.

Why Conventional Treatment Falls Short

Levonorgestrel intrauterine systems (LNG-IUS) and continuous oral progestins reduce bleeding and pain for many women, and tranexamic acid or NSAIDs manage symptoms. Uterine artery embolization (UAE) and MRI-guided focused ultrasound (MRgFUS) offer non-surgical uterine-sparing alternatives, and endometrial ablation can help carefully selected patients [6].

But each option has structural limits in adenomyosis:

• Hormonal suppression treats the stimulus, not the tissue. The ectopic glands persist; symptoms often return after stopping therapy.
• UAE and ablation work best on focal disease. In diffuse adenomyosis the target is the entire myometrium, and shrinkage is partial and often incomplete over time.
• Focused ultrasound has heterogeneous results depending on lesion vascularity and operator experience [7].
• Hysterectomy is definitive but final. For premenopausal women it carries the cost of permanent loss of the uterus — and, in some cases, earlier surgical menopause if the ovaries are affected.

What all these options share is that they manage or remove the endometrial tissue. None of them directly targets the microenvironment — the chronic inflammatory-fibrotic niche that keeps the disease alive and progressive. That's the niche MSC therapy is being studied to address.

How MSCs Might Help: Mechanisms

Mesenchymal stem cells do not act primarily by differentiating into uterine tissue. Their dominant clinical effect is paracrine — they secrete a cocktail of anti-inflammatory mediators, growth factors, and extracellular vesicles that reshape the local microenvironment [8]. Four mechanisms are most relevant to adenomyosis.

1. Anti-inflammatory reprogramming. In adenomyosis tissue, the inflammatory milieu is dominated by pro-inflammatory macrophages (M1 phenotype) and elevated TNF-α, IL-1β, and IL-6. MSCs shift macrophage polarization toward the anti-inflammatory M2 phenotype through secretion of prostaglandin E2, TGF-β, and immunomodulatory extracellular vesicles. In co-culture and animal models of endometriosis and adenomyosis, MSC-conditioned medium reduces pro-inflammatory cytokine levels and normalizes the Th17/Treg balance — the same immunomodulatory signature seen across the gynecological and systemic autoimmune literature [9].

2. Anti-fibrotic modulation. The myometrial stroma in adenomyosis undergoes progressive fibrosis — excess collagen deposition driven by TGF-β/Smad signaling and activated myofibroblasts. MSCs have been shown to attenuate TGF-β–induced myofibroblast activation and upregulate matrix metalloproteinases (MMPs) relative to tissue inhibitors (TIMPs), tipping the balance back toward matrix remodeling rather than stiffening. In fibrotic tissue models, MSC-derived factors reduce collagen I and α-SMA expression — the molecular hallmarks of progressive scarring [10].

3. Restoration of apoptotic sensitivity. A defining molecular feature of adenomyosis and endometriosis is resistance to apoptosis in ectopic endometrial cells — the cells that should clear during the secretory phase instead persist and proliferate. Ectopic foci show upregulated BCL-2 (an anti-apoptotic protein) and downregulated caspase activity. In xenograft and co-culture models, MSC-derived paracrine factors — including TRAIL (TNF-related apoptosis-inducing ligand) and Fas ligand pathway engagement — have been associated with increased apoptotic sensitivity in endometriotic/adenomyotic stromal cells, without significantly affecting normal peritoneal or myometrial cells [11].

4. Modulation of local estrogen autonomy. Adenomyotic lesions express aromatase (CYP19A1), enabling local conversion of androgens to estrogens — a positive feedback loop that sustains lesion growth independent of systemic hormone levels. MSC therapy has been associated with downregulation of aromatase and estrogen receptor-α (ER-α) expression in ectopic tissue in preclinical models, interrupting the autonomous estrogen production loop [12].

What the Evidence Shows

As of mid-2026, the evidence for MSC therapy in adenomyosis is preclinical-to-early-clinical. No randomized controlled trial has completed enrollment specifically in adenomyosis patients. The data come from three sources: (1) the strong and growing preclinical literature in adenomyosis and endometriosis animal models; (2) small case series in closely related conditions (endometriosis, chronic pelvic pain); and (3) direct case reports in adenomyosis specifically.

Preclinical models

Mouse and rabbit models of adenomyosis (typically established by repeated inoculation of endometrial tissue into the myometrium) have shown consistent effects of MSC administration:

• Lesion burden reduction. In murine models, intraperitoneal or intrauterine administration of adipose-derived or bone-marrow-derived MSCs reduced ectopic lesion weight and volume by 30–50% over 8–12 weeks, with associated reductions in aromatase and ER-α expression within lesions [12].
• Inflammatory marker normalization. Serum and tissue levels of TNF-α, IL-6, and IL-1β were significantly reduced in MSC-treated groups relative to vehicle controls, with a concurrent shift in macrophage M1:M2 ratio [9].
• Fibrosis attenuation. Histological scoring showed reduced collagen deposition and lower α-SMA expression in the perilesional myometrium of MSC-treated animals, consistent with the TGF-β/Smad pathway suppression described above [10].
• Junctional zone thickness. In one rabbit model with serial MRI, intrauterine MSC administration was associated with stabilization or reduction of junctional zone thickness over 12 weeks, versus progressive thickening in untreated controls — an imaging endpoint directly relevant to clinical assessment [5].

Direct clinical data in adenomyosis

The most direct human data comes from a 2023 Japanese case series in which 8 women with symptomatic, medically refractory adenomyosis received intrauterine injection of autologous adipose-derived MSCs under hysteroscopic guidance [13]. At 12 months:

• 6 of 8 participants reported substantial improvement in dysmenorrhea and menorrhagia (menses scoring, visual analog scales)
• 5 of 8 showed radiologically measurable reduction in junctional zone thickness on follow-up MRI
• No serious adverse events were reported; minor side effects (transient cramping, mild pelvic discomfort) resolved within days

The sample size is small and the design is uncontrolled, so this is hypothesis-generating, not efficacy-establishing. But it is the first direct human signal that local MSC delivery to adenomyotic tissue is feasible, safe in the short term, and associated with meaningful symptom and imaging improvement in a majority of treated patients.

Indirect clinical signals

Two related conditions provide additional, though less direct, human data:

• Endometriosis. A small open-label pilot (n=15) using intraperitoneal adipose-derived MSCs in women with surgically confirmed endometriosis reported improvement in pain scores and CA-125 levels at 6 months [14]. The shared molecular pathology (impaired apoptosis, chronic inflammation, local estrogen autonomy) makes this biologically relevant to adenomyosis.
• Chronic pelvic pain syndrome. Case series and early trials of systemic and local MSC administration in women with chronic pelvic pain — a syndrome in which adenomyosis is a major underlying cause — have reported pain reduction and quality-of-life improvement at 3–6 months [15].

Treatment Process: What an MSC Protocol Looks Like

At VELAR, an adenomyosis-adjacent MSC protocol (currently offered under research/compassionate-use frameworks, not as standard of care) typically follows this arc:

1. Comprehensive diagnostic workup. T2-weighted MRI with junctional zone measurement, pelvic ultrasound, serum CA-125 and inflammatory markers, complete blood count (to assess anemia from menorrhagia), and a detailed symptom history (menses scoring, dysmenorrhea, dyspareunia, quality of life).
2. Protocol design. Based on disease form (diffuse vs. focal/adenomyoma), symptom severity, and patient goals (symptom control vs. fertility preservation), the treating physician selects the delivery route and dosing. For adenomyosis specifically, the emerging literature points toward local delivery (intrauterine injection under hysteroscopic or ultrasound guidance, or transvaginal percutaneous approaches) as the most biologically plausible route, though systemic IV infusion is also used as an adjunct for systemic inflammatory modulation.
3. Cell preparation. Wharton's-jelly-derived or adipose-derived MSCs, expanded in cGMP Class-100 (ISO Class 5) cleanroom conditions, identity-confirmed by ISCT surface marker panel (CD73⁺/CD90⁺/CD105⁺, CD45⁻/CD34⁻), tested for multi-pathogen safety, and released fresh — never cryopreserved — with >95% viability at delivery.
4. Administration. Under sedation or general anesthesia for intrauterine routes; monitored for hemodynamic stability and immediate local response. Duration typically 20–45 minutes.
5. Follow-up and reassessment. 4-week, 3-month, and 6-month visits with symptom scoring, repeat MRI (junctional zone measurement), and inflammatory marker panels. A second cycle is considered based on trajectory.

Safety, Risks, and Limitations

MSC therapy is not risk-free, and the adenomyosis-specific safety dataset is still small. The most important points, stated plainly:

• No large RCT exists. The human evidence as of 2026 is one small case series (n=8), one pilot in endometriosis (n=15), and indirect signals from chronic pelvic pain studies. This is insufficient to establish efficacy. The therapy remains investigational.
• Long-term safety is unknown. No study has tracked patients beyond 24 months. Theoretical long-term risks — including the small but real risk of aberrant cell behavior (tumor formation, ectopic tissue deposition) — have not been excluded by the current data, though no such events have been reported in the gynecological MSC literature to date [16].
• Pregnancy compatibility is unestablished. For women who wish to preserve fertility, the effect of MSCs on the endometrium and early embryogenesis has not been studied. This is a critical gap.
• Effect size is uncertain. Even in the best case series, improvement was "substantial" for 6 of 8 patients — not complete resolution. The typical effect size in a future RCT is unknown.
• Regulatory status. In most jurisdictions, MSC therapy for adenomyosis is not an approved indication. In Thailand, it is offered under specific clinical frameworks and is subject to the country's medical advertising and practice regulations. Patients should verify the regulatory and licensing status of any facility offering the therapy.

Frequently Asked Questions

What is the difference between adenomyosis and endometriosis?

Both involve endometrial tissue outside the uterine cavity, but adenomyosis is endometrial tissue within the myometrium (the uterine wall), while endometriosis is endometrial tissue outside the uterus (peritoneum, ovaries, bowel, and other pelvic surfaces). They share molecular pathology and can co-occur, but they differ in anatomy, imaging appearance, and surgical management.

Can MSC therapy shrink an adenomyoma?

The preclinical data suggest a reduction in lesion volume and vascularity over 8–12 weeks, and the one human case series showed junctional zone thinning in 5 of 8 patients. Complete resolution is not documented. For a discrete adenomyoma, surgical excision or focused ultrasound remain the more predictable local interventions; MSC therapy is being studied as an adjunct or alternative for diffuse disease.

How many MSC cycles are needed?

Current protocols typically start with a single cycle and reassess at 3–6 months before considering a second. The 2023 case series was a single-cycle study. Multi-cycle dosing is not yet established, and the optimal interval between cycles is unknown.

Is MSC therapy for adenomyosis safe during the menstrual cycle?

Timing relative to the menstrual cycle has not been systematically studied. In the available case series, administration was timed in the early proliferative phase. Practical considerations (cervical patency, baseline bleeding, imaging window) make timing a physician-managed decision.

How much does MSC therapy cost in Bangkok?

Costs vary by cell source, delivery route, number of cycles, and facility. At VELAR, a consultation includes a candid discussion of total expected cost — including cell preparation, administration, imaging, and follow-up — before any commitment. It is generally in the range of established regenerative medicine protocols, not a one-day procedure.

What is the most common reason to choose hysterectomy over MSC therapy?

When adenomyosis is severe, medically refractory, and the patient has completed childbearing and does not wish to preserve the uterus, hysterectomy remains the only definitive cure. MSC therapy is not a substitute for that decision; it is an alternative pathway for patients who want to preserve uterine function and accept the uncertainty of an investigational protocol.

How to Evaluate a Clinic Offering MSC Therapy for Adenomyosis

• Is the indication named explicitly? A reputable facility will discuss adenomyosis as a distinct condition, not bundle it vaguely under "pelvic pain" or "women's health." Ask to see their rationale for choosing MSCs over or alongside standard options.
• Is the cell source and manufacturing standard disclosed? cGMP-class cleanroom (ISO Class 5), ISCT marker verification, multi-pathogen testing, and a documented release process with viability >95% are baseline expectations. Fresh, never-frozen delivery is a quality differentiator.
• Is the delivery route justified for adenomyosis specifically? Local (intrauterine) delivery is the biologically plausible route for this condition. A protocol that uses only systemic IV infusion for adenomyosis without acknowledging the local-delivery literature is worth questioning.
• Is the follow-up plan concrete? Named timepoints, named imaging (T2 MRI junctional zone), named lab panels, and a documented decision point for a second cycle are hallmarks of a structured protocol.
• Are limitations stated honestly? The best facilities will tell you the therapy is investigational, that no RCT exists, and what the expected effect size might be. Facilities that promise "cure" or "guaranteed shrinkage" are red flags.

Limitations of This Review

This article is an educational review, not a treatment recommendation. The adenomyosis-specific MSC literature is small, preclinical-to-early-clinical, and not yet sufficient to support a guideline-level recommendation. Individual outcomes vary, and the optimal protocol — cell source, dose, delivery route, cycle interval — has not been established. Patients considering this pathway should do so with a treating physician who can contextualize the evidence against their specific disease form, symptom profile, and fertility goals, and who is transparent about what the data can and cannot support.